AbolerIS Pharma

Foundation date

28/11/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

Latest news

  • Antonin (Tony) de Fougerolles appointed as new Chair of etherna

    Tuesday July 16th 2024

  • ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust

    Tuesday July 16th 2024

  • Ghent University spin-off Trince wins Nature Spinoff Prize

    Monday July 15th 2024